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Abstract 
 
Objectives: In a context marked by major changes in the field of HIV and in the general 
socioeconomic context, this study aimed at investigating changes in the employment situation of 
people living with HIV (PLWHIV) in France since the early 2000s. 
Design:  Repeated cross-sectional survey among two nationally representative samples of PLWHIV 
followed at hospital in France in 2003 (N=2,932) and 2011 (N=3,022). 
Methods:  Differences between 2003 and 2011 in 1) rates of employment, unemployment and 
inactivity and 2) rates of work cessation and access to work following HIV diagnosis were 
measured using two-step multivariate Poisson regression models adjusted for individual socio-
demographic determinants of position on the labor market, and then additionally for health 
status characteristics. 
Results:  Overall, among working-age PLWHIV 60.9% in 2003 and 59.6% in 2011 were employed; 
12.6% and 15.8%, respectively, were unemployed; and 26.5% and 24.6%, respectively, were 
inactive. Adjusting for socio-demographic determinants of position on the labor market, while 
employment rate was not different in 2011 compared to 2003, inactivity rate significantly 
decreased (adjusted Prevalence Rate Ratio: 0.83, 95% Confidence Interval: [0.72-0.96]) and 
unemployment rate significantly increased (1.28 [1.04-1.57]). After additional adjustment for 
health status characteristics, the difference was no longer significant for inactivity (0.89 [0.77-
1.03]) but remained significant for unemployment (1.55 [1.24-1.93]). Compared to 2003, in 2011 
transitions to unemployment following HIV diagnosis tended to be more frequent (1.58 [0.92-
2.68]) and access to work was significantly less frequent (0.57 [0.33-0.99]). 
Conclusions:  Improvements in HIV care have not translated into improvements in PLWHIV’s 
situation regarding employment.  
Keywords: Employment status; Disability; Socioeconomic factors; France; HIV infection 
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Introduction 
In the general population, work constitutes a central dimension of individuals living conditions 
by providing them with financial support, social status and identity [1]. In addition, employment 
status and, for those employed, working conditions and organization have major effects on health 
[2, 3]. Among people living with HIV (PLWHIV) as well, employment status has been shown to be 
an independent predictor of adherence to treatment, morbidity and mortality [4-7].  
Studies conducted in various Western countries in the early 2000s provided evidence that 
early in the combined antiretroviral therapy (cART) era, HIV infection negatively affected 
individual chances of maintaining in and accessing/returning to employment [8-12]. This 
deleterious effect of HIV infection on employment was shown to occur from the very first months 
following disease onset [13] through various mechanisms including disease severity and HIV-
related discrimination [14]. As in the general population, socio-demographic characteristics 
including age, sex, education, country of citizenship and family status constitute major 
determinants of PLWHIV’s position on the labor market [11, 15]. HIV-infected women, migrants 
and drug users are particularly disadvantaged compared to men who have sex with men [11]. 
Major changes have occurred over the past decade, both in the field of HIV and in the broader 
general socioeconomic context, which may have resulted in changes in the burden of HIV 
infection on employment. First, the sustained use of cART has resulted in marked decreases in 
HIV-related morbidity and mortality [16, 17], but also in a rise in the frequency of various non-
AIDS related conditions [18, 19] which substantially affect PLWHIV’s chances of maintaining in 
employment [15]. Second, in addition to PLWHIV’s ageing, the changing face of the HIV epidemics 
in Europe has resulted in increasing proportions of persons with a disadvantaged position on the 
labor market among PLWHIV - especially women and migrants originating from Sub-Saharan 
Africa [20, 21]. Third, the economic crisis of 2008 has had severe and long-lasting effects on 
employment throughout Europe [22], and people affected by a chronic condition may be 
particularly affected [23-25]. 
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In this changing context, the present study aimed at investigating changes in PLWHIV’s 
situation regarding employment since the early 2000s in France. More specifically, our objectives 
were to measure changes over time in 1) PLWHIV’s rates of employment, unemployment and 
inactivity and 2) early labor market transitions following HIV diagnosis, accounting for changes in 
individuals’ socio-demographic determinants of position on the labor market and health status. 
We hypothesized that the potentially beneficial effects of recent HIV care improvements on 
PLWHIV’s situation regarding employment may have been counterbalanced by concurrent 
changes in the characteristics of the HIV epidemics and the general socioeconomic context.  
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Methods 
Study design 
The study was based on data of a repeated cross-sectional survey conducted among two large 
nationally representative samples of HIV-infected people followed at hospital in France in 2003 
and 2011, with the primary aim of assessing the various dimensions of socioeconomic conditions 
and health of PLWHIV in France in their diversity and their changes over time. Both surveys were 
conducted among random samples of hospital outpatients aged 18 or older, diagnosed HIV-
infected for at least 6 months, and either French-citizens or immigrants living in France for at least 
6 months. The VESPA-2003 survey was conducted between December 2002 and September 2003 
amongst 2,932 PLWHIV recruited in 102 hospital departments in mainland France. Its 
methodology has been extensively described elsewhere [26]. The VESPA-2011 survey was 
conducted between April 2011 and January 2012 amongst 3,022 PLWHIV recruited in 73 hospital 
departments in mainland France, using a similar design as detailed elsewhere [27]. In both 
surveys, participants answered a standardized questionnaire administered face-to-face by a 
trained interviewer including detailed questions on sociodemographic characteristics, living 
conditions, health and healthcare. To allow comparisons, a number of key questions were kept 
the same between surveys. Participants were additionally asked to complete a self-administered 
questionnaire including an assessment of health-related quality of life (HRQL) using generic scales 
from the Medical Outcomes Study (MOS): the 36-item Short-Form health survey instrument (SF-
36) [28] in VESPA-2003 and its 12-item subset (SF-12) [29] in VESPA-2011. Both scales have been 
shown to have discriminant validity and to provide appropriate measures of HRQL. Clinical and 
laboratory information were documented from medical records.  
Data were weighted to account for sampling design and non-participation. Details about the 
weighting procedure are provided elsewhere [27]. Both surveys received approval from the 
French Advisory Committee on Information Processing in Material Research in the Field of Health 
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(CCTIRS) and met the ethical requirements of the French National Commission for Computing and 
Liberties (CNIL). 
Variables of interest 
Employment status at the time of interview was documented for all participants, based on 
similar questions in both surveys. In line with the definition of the International Labour 
Organization, employment status was categorized in two steps as follows. First, participants were 
considered employed if they reported having a job (either paid or voluntary), regardless of 
professional status and working time (full time/part time), or if they were on sick leave for less 
than 6 months. Then, among participants who were not employed, individuals were categorized 
as either unemployed if they reported having actively sought work within the preceding 3 months 
or inactive otherwise, including students, retirees, people on disability (recipients of a disability 
benefit or on sick leave for more than 6 months) and those with family responsibilities. In 
addition, employment status at the time of HIV diagnosis (employed or not) was documented for 
respondents diagnosed HIV-infected within the 36 months preceding the survey.  
We considered socio-demographic characteristics (age, sex, citizenship, educational level and 
household composition) and lifetime history of intravenous drug use as indicators of socio-
demographic determinants of individuals’ position on the labor market. Educational level was 
measured using maximum attained level of education in VESPA-2003 and highest diploma 
obtained in VESPA-2011, and dichotomized as low (primary or secondary education in VESPA-
2003; high school diploma or lower in VESPA-2011) or high (higher education in VESPA-2003; 
tertiary degree in VESPA-2011). Health status characteristics documented from medical records 
included indicators of HIV disease advancement (duration since HIV diagnosis at the time of the 
survey; immune status at the time of diagnosis; status regarding combination antiretroviral 
therapy (cART) and HIV viral load (VL) at the time of the survey) and information on history of 
Hepatitis C. For participants who completed the self-administered questionnaire, the physical 
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component summary (PCS) for physical HRQL and the mental component summary (MCS) for 
mental HRQL were computed using the 12 items common to the SF-12 and the SF-36 scales. 
These scores range from 0 to 100, with higher values denoting better HRQL. Impaired physical or 
mental HRQL was defined by a score below the first quartile of the distribution by age and sex in 
the French general population of, respectively, the PCS and the MCS [30]. 
Statistical Analyses 
Analyses included participants of the VESPA-2003 and VESPA-2011 surveys of working-age (25-
64 years old) at the time of the survey and diagnosed HIV-infected in 1996 or later, i.e. in the era 
of cART availability. Individuals with missing information for variables with <1% missing values 
were excluded.  
Employment, unemployment and inactivity rates (each expressed as a percentage of the whole 
study population) were estimated in 2003 and in 2011, overall and according to individuals’ socio-
demographic determinants of position on the labor market and health status characteristics. 
Adjusted prevalence rate ratios (aPRR) comparing overall employment, unemployment and 
inactivity rates between 2003 and 2011 were assessed using three separate multivariate Poisson 
regression models with a robust variance estimator [31]. Each model considered the whole study 
population and compared the probability of being, respectively, employed (vs. unemployed or 
inactive), unemployed (vs. employed or inactive), or inactive (vs. employed or unemployed) in 
2011 versus 2003. In a first step, models were adjusted for individual socio-demographic 
determinants of position on the labor market, thus providing estimates of the comparison of 
PLWHIV’s employment status between 2003 and 2011 controlling for changes in individuals 
profile over time. Then, in order to estimate whether changes in PLWHIV’s health contributed to 
differences in employment status between 2003 and 2011, additional adjustment for health 
status characteristics was performed. 
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Labor market transitions following HIV diagnosis were assessed among the sub-sample of 
participants diagnosed HIV-infected within the 36 months preceding the survey in VESPA-2003 
and VESPA-2011. Rates of work cessation (distinguishing between transitions from employment 
to i) unemployment and ii) inactivity) and access to work (transition from non-employment to 
employment) between HIV diagnosis and survey time were compared between 2003 and 2011, 
using multivariate Poisson regression models adjusted for individual socio-demographic 
determinants of position on the labor market and health status characteristics. 
Individuals with unknown CD4 at time of diagnosis or unknown VL at time of the survey and 
those who did not complete the self-administered questionnaire were included in the analyses 
using missing categories for immune status at diagnosis, status regarding cART and VL at the time 
of the survey, and HRQL, respectively. Because these information may not be missing at random, 
we conducted sensitivity analyses assigning all participants with missing data for each of these 
three covariates to either the least favorable (ie, <200 CD4/mm3 or AIDS; not on ART; impaired 
physical and mental HRQL, respectively) or the most favorable situation (ie, ≥500 CD4/mm3; on 
ART and VL<400/ml; normal physical and mental HRQL, respectively) in separate analyses. 
All analyses were performed using Stata 12®(Stata Corporation, College Station, TX) and 
accounted for the complex sampling design and data weighting so that estimates are 
representative of the whole population of HIV-infected people followed at hospital in France.  
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Results  
Characteristics of the study population 
Of a total of 2,676 participants (1,010 participants of VESPA-2003 and 1,666 participants of 
VESPA-2011) of working-age at the time of interview and diagnosed HIV-infected in 1996 or later, 
16 individuals with missing information on educational level (n=3) or Hepatitis C history (n=13) 
were excluded. The 2,660 participants included were predominantly men (64.8%); 28.0% were 
citizens of a country of sub-Saharan Africa and more than a third (36.2%) were men who have sex 
with men. As shown in Table 1, socio-demographic and health characteristics of PLWHIV differed 
between 2003 and 2011. As compared to 2003, in 2011 PLWHIV were older (median age: 43 
versus 39 years, p<0.001) and more frequently women (37.2% versus 32.1%, p=0.05) and citizens 
of a country of sub-Saharan Africa (31.0% versus 22.9%, p<0.001). In addition, in 2011 PLWHIV 
had been diagnosed HIV-positive for a longer time than in 2003 (median time since HIV diagnosis: 
7.4 versus 3.8 years, p<0.001), their CD4 cell count at diagnosis was higher (median: 358 versus 
303, p <0.001) and they were more frequently in virological success (83.2% versus 62.3%, 
p<0.001). 
Employment status at the time of the survey 
Overall, approximately six PLWHIV out of ten were employed in both surveys (60.9% in VESPA-
2003 and 59.6% in VESPA-2011, p=0.56). Among them, 6.2% and 4.7%, respectively, were on sick 
leave at the time of interview. The rate of unemployment increased by 3.2 points, from 12.6% in 
2003 to 15.8% in 2011 (relative change: +25.2%, p=0.04) and the rate of inactivity decreased by 
1.9 points, from 26.5% to 24.6%, respectively (relative change: -7.2%, p=0.34). Main reasons for 
inactivity were disability (almost half of the inactive in 2003 and 2011 – 47.0% and 48.4%, 
respectively, p=0.76) and retirement (10.2% and 25.6%, respectively, p=0.001).  
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As shown in Table 2, in 2003 and 2011 employment status markedly differed according to 
socio-demographic characteristics. Employment rates were the highest among men (67.0% in 
VESPA-2003 and 64.7% in VESPA-2011), French-nationals (67.6% and 63.9%, respectively), 
individuals aged 40-49 years (65.3% and 64.5%, respectively), those highly educated (72.5% and 
71.6%, respectively) and those living in cohabiting partnership without children (71.6% and 66.1%, 
respectively). Unemployment was particularly high among women (16.4% and 21.0%, respectively 
in 2003 and 2011), individuals aged less than 40 years (14.9% and 22.5%, respectively) and those 
originating from sub-Saharan Africa (22.8% and 26.5%, respectively). Inactivity was particularly 
frequent among women (35.7% and 28.0%, respectively), non-African immigrants (42.2% and 
35.1%, respectively), individuals aged 50 years or more (42.3% and 40.2%, respectively) and those 
low-educated (31.9% and 28.5%, respectively). History of intravenous drug use was also 
associated with high rates of inactivity (53.4% and 50.0%, respectively). Employment status 
additionally differed according to health status characteristics, with higher employment rates 
among individuals with the most favorable indicators regarding HIV disease advancement, 
comorbidity and health-related quality of life. 
Adjusting for socio-demographic determinants of position on the labor market, the 
employment rate of PLWHIV was not different in 2011 as compared to 2003 (aPRR: 1.03, 95% 
Confidence Interval: 0.96 to 1.10). Though, the rate of inactivity significantly decreased between 
2003 and 2011 (aPRR: 0.83, 95%CI: 0.72 to 0.96), and the rate of unemployment significantly 
increased (aPRR 1.28, 95%CI: 1.04 to 1.57) (Tables 3 and 4). 
After additional adjustment for health status characteristics, the difference in inactivity rate 
between 2003 and 2011 was no longer significant (aPRR: 0.89, 95%CI: 0.77 to 1.03). In contrast, 
the unemployment rate remained significantly higher in 2011 compared to 2003 (aPRR: 1.55, 
95%CI: 1.24 to 1.93). These results remained consistent in sensitivity analyses. 
Labor market transitions following HIV diagnosis 
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A total of 427 participants in VESPA-2003 and 366 participants in VESPA-2011 had been 
diagnosed HIV-infected within the 36 months preceding the interview. These recently diagnosed 
individuals did not differ between 2003 and 2011 regarding socio-demographic determinants of 
position on the labor market (supplementary Table S1); though, compared to 2003 those included 
in 2011 were less likely to have reached an advanced stage of HIV disease at the time it was 
diagnosed (29.1% versus 37.6%, p=0.06) and to have a history of Hepatitis C (3.0% versus 6.0%, 
p=0.06), and more likely to be in virological success (69.7% versus 57.1%, p=0.007). 
Among recently diagnosed participants employed at the time of HIV diagnosis, 10.1% in 
VESPA-2003 and 19.2% in VESPA-2011 had turned unemployed by the time of interview (p=0.01); 
and 14.8% and 15.4%, respectively, had become inactive (p=0.88) (Figure 1). Adjusting for 
individuals’ socio-demographic determinants of position on the labor market and health status 
characteristics, the rate of transition from employment to unemployment between times of HIV 
diagnosis and interview tended to be higher among participants of VESPA-2011 compared to 
participants of VESPA-2003 (aPRR: 1.58, 95%CI: 0.92 to 2.68). The rate of transition from 
employment to inactivity did not differ between participants of both surveys (aPRR: 1.05, 95%CI: 
0.63 to 1.76). 
Among recently diagnosed participants not employed at the time of HIV diagnosis, the proportion 
who had accessed employment by the time of interview was 29.0% in VESPA-2003 and 21.2% in 
VESPA-2011 (Figure 1). Adjusting for individuals’ socio-demographic determinants of position on 
the labor market and health status characteristics, the rate of access to work between times of 
HIV diagnosis and interview was significantly lower among participants of VESPA-2011 compared 
to participants of VESPA-2003 (aPRR: 0.54, 95%CI: 0.32 to 0.90). 
These results remained consistent in sensitivity analyses. 
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Discussion  
Our results indicate that in France, the employment rate of PLWHIV has remained consistently 
low over the past decade. Though, this apparent stability masks diverging trends over time in the 
labor market position of PLWHIV who are out of employment. Indeed, we found that between 
2003 and 2011, while economic inactivity decreased, unemployment increased. This suggests that 
despite the major improvements in HIV care and treatments occurred over the past decade, the 
employment of PLWHIV, a population which is mainly made of working age people, still remains 
problematic in the current context and therefore deserves a special attention. 
The VESPA-2003 and VESPA-2011 studies, because they were conducted at two different time 
points using similar study design and questions, provide unique datasets to investigate changes in 
PLWHIV health and living conditions over a period marked by major changes both in the field of 
HIV and more broadly in terms of socioeconomic, political and social context. The national-
representative nature of the two datasets constitutes a major strength of our study, as well as the 
availability of detailed individual information allowing distinguishing between unemployment and 
economic inactivity and accounting for changes over time in PLWHIV’s sociodemographic and 
health profiles. However, it should be acknowledged that the study is restricted to HIV-infected 
people attending hospital for HIV care. Nevertheless, HIV care is essentially provided at hospital in 
France and since 2006 the experts have recommended that all PLWHIV have at least an annual 
checkup at hospital [32], suggesting that our estimates are likely to apply to the vast majority of 
PLWHIV in care in France. In addition, the causal interpretation of our findings on changes over 
time should remain cautious, especially because analyses consisted of comparisons between two 
cross-sectional surveys rather than on individual longitudinal data. Furthermore, the changes we 
report among PLWHIV may partly reflect changes occurred more generally in the French general 
population. Investigating the proper role of HIV infection on these changes would have required a 
control group of HIV-negative individuals. 
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The employment rates of approximately 60% we report among PLWHIV in 2003 and 2011 are 
much lower than the corresponding rates in the French general population aged 20-64 years 
(69.7% in 2003 and 69.3% in 2011) [33]. This is consistent with previous studies which reported a 
lower employment rate among PLWHIV compared to the general population in France [15] as well 
as in other European countries including Denmark [34], Belgium [35], Spain [36] or UK [37]. In 
contrast, our findings provide evidence of high rates of both economic inactivity and 
unemployment among PLWHIV. The inactivity rates we report are substantially higher among 
PLWHIV aged 25-49 years compared to the French general population of similar age range (23% in 
2003 and 18% in 2011 versus 12% and 11%, respectively, in the general population [38]), while 
among people aged 50-64 years figures appear less contrasted, reaching more than forty percent 
of individuals in this age category both among PLWHIV and in the general population (42% and 
40% versus 43% and 41% [38], respectively). Even in the era of highly potent antiretroviral 
treatments, inactivity appears to be primarily driven by disability among PLWHIV, probably as a 
consequence of HIV disease itself but also comorbidities. Similarly, disability retirement was 
reported to be increased among PLWHIV compared to the general population in Denmark [34]. By 
providing evidence of high rates of unemployment among PLWHIV (12.6% in 2003 and 15.8% in 
2011, compared to 5.7% and 6.1%, respectively, in the general population [38]), our results 
additionally suggest that the low employment rate of PLWHIV results not only from their 
exclusion from the labor market but also from a decreased employability of those who remain in 
the labor force.  
We found that controlling for individual socio-demographic determinants of position on the 
labor market, the inactivity rate of PLWHIV, although persistently high, significantly decreased 
between 2003 and 2011. This decrease was no longer significant after accounting for health status 
characteristics, suggesting that it likely results from improvements in HIV care occurred over the 
study period. Such a finding, by providing evidence for PLWHIV’s increased ability to work, is 
consistent with previous findings supporting the ‘normalization’ of PLWHIV’s life in the era of 
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cART [39]. This decrease may also reflect changes in eligibility requirements for disability 
introduced in France in 2005 [40], which may have resulted in reduced access to disability 
benefits for PLWHIV. Yet, among participants of the VESPA studies the proportion of recipients of 
a disability benefit did not decrease between 2003 (15.7%) and 2011 (18.1%), suggesting that 
such changes are unlikely to explain the decrease in inactivity we report.  
In contrast with inactivity figures, unemployment significantly increased between 2003 and 
2011. Previous reports showed that adverse employment outcomes arise very early in the course 
of HIV disease [9, 10, 13, 15, 34]. Our results on early labor market transitions (i.e., within the first 
36 months) following HIV diagnosis confirm the high frequency of such early changes; and 
furthermore suggest that the increase in unemployment we report is likely to result from lower 
chances of both maintaining in employment and accessing (or returning) to work in 2011 
compared to 2003. This may be related to various underlying mechanisms. First, the increase we 
report in terms of adverse labor market transitions may result from the overall deterioration of 
the economic situation generally affecting the French labor market since 2008 [38]. Second, this 
may reflect the increasing burden of comorbidities, including e.g. cardiovascular disease or 
depression, which have been shown to impair PLWHIV’s employment status [15]. Indeed, in our 
study although analyses were adjusted for health status as measured by HIV disease 
advancement, hepatitis C coinfection and health-related quality of life, differences in 
comorbidities over time could not be accounted for since the information was not available in the 
2003 survey. Third, experiences of discrimination related either to HIV status or other 
characteristics of the individuals, which constitute independent predictors of employment loss 
among PLWHIV [14], were very frequent in France in 2011. Indeed, 24% of the VESPA-2011 
respondents having applied for a job reported having been discriminated against when seeking a 
job in the past two years , and 6% of the participants reported experiences of discrimination in 
their work environment (if any) [41]. Though, because comparable figures were not available in 
the VESPA-2003 study, we were not able to measure their contribution to the reported trends.  
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In conclusion, our study suggests that improvements in HIV care occurred since the early 2000s 
have not translated into improvements in PLWHIV’s situation regarding employment. Although 
PLWHIV have seen their ability to work increased in the recent years, these improvements appear 
to have been offset by increasing barriers to maintain in and/or access to employment. The 
respective roles of socioeconomic recession, comorbidities and discrimination deserve to be 
further investigated to help address the issue of employment of PLWHIV in the current context.  
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Table 1. Participants’ socio-demographic determinants of position on the labor market and health 
status characteristics, VESPA-2003 and VESPA-2011 surveys 
 
VESPA-2003 
a
 
(N=1,010) 
 
VESPA-2011 
a
 
(N=1,650) 
 P-value 
b 
Socio-demographic determinants of position on the labor market  
 
Sex 
 
 
 
 
 
Men 67.9  62.8  0.046 
Women 32.1  37.2  
 
Age (years) 
 
 
 
  
25-39 52.4  35.1  <0.001 
40-49 29.5  35.9  
 
50-64 18.1  29.0  
 
Country of citizenship     
 
France 67.2  62.4  <0.001 
Sub-Saharan Africa 22.9  31.0  
 
Other 9.9  6.6  
 
Educational level 
 
 
 
 
 
High  31.1  29.1  0.33 
Low 68.9  70.9  
 
Household composition   
 
  
Single, no children 37.7  37.1  0.52 
Single with children 9.6  11.8  
 
Cohabiting partner, no children 23.9  23.2  
 
Cohabiting partner and children 16.3  17.0  
 
Other cohabiting adults 12.5  10.9  
 
History of intravenous drug use 
 
 
 
 
 
No 94.2  94.1  0.91 
Yes 5.8  5.9  
 
Health status 
 
 
 
 
 
Duration since HIV diagnosis 
 
 
 
  
Less than 3 years 39.1  17.9  <0.001 
3 years or more 60.9  82.1  
 
Immune status at HIV diagnosis 
 
 
 
  
<200 CD4/mm
3
 or AIDS 33.1  28.5  0.007 
200-349 CD4/mm
3
 19.4  16.6  
 
350-499 CD4/mm
3
 13.5  18.1  
 
≥500 CD4/mm
3
 23.1  22.9  
 
Missing 10.9  13.9  
 
ART status and HIV viral load (VL)   
 
  
On ART, VL <400 copies/ml 62.3  83.2  <0.001 
On ART, VL ≥400 copies/ml 12.1  4.2  
 
Not on ART 23.0  10.3  
 
Missing 2.6  2.3  
 
History of Hepatitis C 
 
 
 
  
No 90.3  92.1  0.15 
Yes 9.7  7.9  
 
Health-Related Quality of Life (HRQL)   
 
  
Normal 22.1  21.4  <0.001 
Impaired mental HRQL 12.0  8.4  
 
Impaired physical HRQL 15.6  22.5  
 
Impaired physical and mental HRQL 16.3  20.0  
 
Missing 34.0  27.7  
 a
 Weighted percentages 
b
 Chi-square test
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Table 2. Employment status according to participants’ socio-demographic determinants of position on the labor market and health status characteristics, VESPA-2003 
and VESPA-2011 surveys 
  VESPA-2003  VESPA-2011 
  
%
a
  
Employed 
%
a
  
Unemployed 
%
a
  
Inactive 
P- 
value 
b 
 %
a
  
Employed 
%
a
  
Unemployed 
%
a
  
Inactive 
P- 
value 
b 
Socio-demographic determinants of position on the labor market        
Sex  
  
 
 
   
  
Men 67.0 10.8 22.2 <0.001  64.7 12.6 22.6 <0.001 
Women 47.9 16.4 35.7 
 
 51.0 21.0 28.0 
 
Age (years)  
   
 
    
25-39 61.4 14.9 23.7 <0.001  61.3 22.5 16.2 <0.001 
40-49 65.3 12.4 22.2 
 
 64.5 15.3 20.2 
 
50-64 51.7 5.9 42.3 
 
 51.6 8.3 40.2 
 
Country of citizenship  
   
 
    
France 67.6 9.2 23.1 <0.001  63.9 10.0 26.1 <0.001 
Sub-Saharan Africa 47.6 22.8 29.6 
 
 54.2 26.5 19.4 
 
Other 45.7 12.1 42.2 
 
 44.0 20.8 35.1 
 
Educational level  
   
 
    
High  72.5 12.7 14.7 <0.001  71.6 13.0 15.4 <0.001 
Low 55.5 12.6 31.9 
 
 54.6 16.9 28.5 
 
Household composition  
   
 
    
Single, no children 64.2 9.7 26.1 <0.001  59.4 13.9 26.8 <0.001 
Single with children 42.4 15.6 42.0 
 
 45.6 31.7 22.7 
 
Cohabiting partner, no children 71.6 9.1 19.3 
 
 66.1 8.2 25.7 
 
Cohabiting partner and children 59.4 16.1 24.5 
 
 63.8 15.9 20.2 
 
Other cohabiting adults 46.1 21.6 32.3 
 
 55.3 20.7 24.0 
 
History of intravenous drug use  
   
 
    
No 62.7 12.5 24.8 <0.001  61.2 15.7 23.1 0.02 
Yes 32.3 14.3 53.4 
 
 33.7 16.3 50.0 
 
Health status  
   
 
    
Duration since HIV diagnosis  
   
 
    
Less than 3 years 56.0 16.4 27.5 0.01   56.3 24.8 18.9 <0.001 
3 years or more 64.0 10.2 25.8    60.3 13.8 25.8   
Immune status at HIV diagnosis  
   
 
    
<200 CD4/mm
3
 or AIDS 57.1 10.0 32.9 0.004   50.6 17.1 32.3 <0.001 
200-349 CD4/mm
3
 58.6 15.5 25.8 
 
 61.0 17.4 21.5 
 
350-499 CD4/mm
3
 64.8 10.8 24.4 
 
 70.0 11.0 18.9 
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≥500 CD4/mm
3
 69.9 12.9 17.1 
 
 63.0 15.4 21.6 
 
ART status and HIV viral load (VL)  
   
 
    
On ART, VL <400 copies/ml 64.0 11.0 25.0 0.03   60.8 14.1 25.0 0.01 
On ART, VL ≥400 copies/ml 48.6 16.6 34.8 
 
 48.8 29.2 22.1 
 
Not on ART 59.5 15.2 25.3 
 
 55.8 24.7 19.5 
 
History of Hepatitis C  
   
 
    
No 62.9 12.7 24.5 <0.001  61.0 15.2 23.7 0.002 
Yes 42.4 11.9 45.7 
 
 42.2 22.3 35.5 
 
Health-Related Quality of Life (HRQL)  
   
 
    
Normal 78.3 11.5 10.2 <0.001  72.1 11.7 16.2 0.002 
Impaired mental HRQL 73.9 11.6 14.6 
 
 65.3 16.8 18.0 
 
Impaired physical HRQL 63.0 10.0 27.0 
 
 63.3 12.8 23.9 
 
Impaired physical and mental HRQL 43.9 15.3 40.9 
 
 52.9 18.0 29.1 
 a
 Weighted percentages 
b
 Chi-square test
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Table 3. Prevalence rate ratio of inactivity in 2011 versus 2003, adjusted for individual socio-demographic 
determinants of position on the labor market (Model 1) and additionally for health status characteristics 
(Model 2) 
  Model 1   Model 2 
 
aPRR [95% CI] 
 
aPRR [95% CI] 
Survey year           
2003 1 
  
1 
 2011 0.83* [0.72; 0.96] 
 
0.89 [0.77;1.03] 
Socio-demographic determinants of position on the labor market 
  
Sex 
     
  Men 1 
  
1 
   Women 1.53* [1.30; 1.80] 
 
1.54* [1.32;1.80] 
Age (years) 
     
  25-39 0.92 [0.77; 1.11] 
 
0.97 [0.80;1.17] 
  40-49 1 
 
 
1 
   50-64 2.13* [1.79; 2.54] 
 
2.21* [1.87;2.63] 
Country of citizenship 
     
  France 1 
 
 
1 
   Sub-Saharan Africa 0.89 [0.74; 1.08] 
 
0.74* [0.61;0.89] 
  Other 1.35* [1.09; 1.67] 
 
1.18 [0.95;1.46] 
Educational level 
     
  High  1 
 
 
1 
   Low 1.74* [1.41; 2.14] 
 
1.66* [1.35;2.04] 
Household composition 
     
  Single, no children 1.15 [0.96; 1.37] 
 
1.14 [0.95;1.36] 
  Single with children 1.07 [0.82; 1.39] 
 
1.01 [0.78;1.31] 
  Cohabiting partner, no children 1 
 
 
1 
   Cohabiting partner and children 0.93 [0.72; 1.19] 
 
0.90 [0.70;1.16] 
  Other cohabiting adults 1.13 [0.87; 1.46] 
 
1.10 [0.86;1.42] 
History of intravenous drug use 
     
  No 1 
  
1 
   Yes 2.01* [1.65; 2.45] 
 
1.70* [1.34;2.17] 
Health status 
     
Duration since HIV diagnosis 
     
  Less than 3 years 
   
1.01 [0.85;1.20] 
  3 years or more 
   
1 
 
Immune status at HIV diagnosis 
     
  <200 CD4/mm
3
 or AIDS 
   
1.58* [1.25;1.99] 
  200-349 CD4/mm
3
 
   
1.11 [0.84;1.47] 
  350-499 CD4/mm
3
 
   
1.07 [0.83;1.38] 
  ≥500 CD4/mm
3
 
   
1 
   Missing 
   
1.33* [1.03;1.72] 
ART status and HIV viral load (VL) 
     
  On ART, VL <400 copies/ml 
   
1 
   On ART, VL ≥400 copies/ml 
   
1.09 [0.86;1.38] 
  Not on ART 
   
1.23 [0.96;1.58] 
  Missing 
   
1.86* [1.27;2.72] 
History of Hepatitis C 
     
  No 
   
1 
   Yes 
   
1.01 [0.80;1.29] 
Health-Related Quality of Life (HRQL) 
   
  
  Normal 
   
1 
 
  Impaired mental HRQL 
   
1.27 [0.87;1.87] 
  Impaired physical HRQL 
   
1.72* [1.30;2.28] 
  Impaired physical and mental HRQL 
 
  
2.35* [1.82;3.03] 
  Missing       2.10* [1.65;2.67] 
aPRR: adjusted prevalence rate ratio CI: confidence interval   *p<0.05  
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Table 4. Prevalence rate ratio of unemployment in 2011 versus 2003, adjusted for individual socio-
demographic determinants of position on the labor market (Model 1) and additionally for health status 
characteristics (Model 2) 
  Model 1   Model 2 
 
aPRR [95% CI] 
 
aPRR [95% CI] 
Survey year           
  2003 1 
  
1 
   2011 1.28* [1.04; 1.57] 
 
1.55* [1.24;1.93] 
Socio-demographic determinants of position on the labor market  
 
Sex 
   
 
 
  Men 1 
  
1 
   Women 0.93 [0.71; 1.21] 0.93 [0.72;1.21] 
Age (years) 
   
 
 
  25-39 1.21 [0.96; 1.53] 
 
1.15 [0.91;1.44] 
  40-49 1 
 
 
1 
   50-64 0.58* [0.42; 0.82] 0.59* [0.42;0.83] 
Country of citizenship 
   
 
 
  France 1 
 
 
1 
   Sub-Saharan Africa 2.11* [1.62; 2.74] 
 
2.16* [1.65;2.81] 
  Other 1.52* [1.06; 2.17] 
 
1.52* [1.06;2.18] 
Educational level 
   
 
 
  High  1 
 
 
1 
   Low 0.96 [0.74; 1.23] 1.00 [0.77;1.28] 
Household composition 
   
 
 
  Single, no children 1.30 [0.92; 1.84] 
 
1.27 [0.90;1.79] 
  Single with children 2.11* [1.43; 3.13] 
 
2.03* [1.38;2.99] 
  Cohabiting partner, no children 1 
 
 
1 
   Cohabiting partner and children 1.38 [0.94; 2.04] 
 
1.38 [0.95;2.02] 
  Other cohabiting adults 1.86* [1.28; 2.71] 
 
1.69* [1.15;2.49] 
History of intravenous drug use 
   
 
 
  No 1 
  
1 
   Yes 1.35 [0.92; 1.99] 
 
1.02 [0.64;1.65] 
Health status 
   
 
 
Duration since HIV diagnosis 
   
 
 
  Less than 3 years 
   
1.46* [1.15; 1.85] 
  3 years or more 
   
1 
 
Immune status at HIV diagnosis 
   
 
 
  <200 CD4/mm
3
 or AIDS 
   
1.00 [0.73;1.38] 
  200-349 CD4/mm
3
 
   
1.16 [0.83;1.63] 
  350-499 CD4/mm
3
 
   
0.75 [0.53;1.07] 
  ≥500 CD4/mm
3
 
   
1 
   Missing 
   
1.19 [0.82;1.72] 
ART status and HIV viral load (VL) 
   
 
 
  On ART, VL <400 copies/ml 
   
1 
   On ART, VL ≥400 copies/ml 
   
1.52* [1.11;2.07] 
  Not on ART 
   
1.32 [0.98;1.78] 
  Missing 
   
0.73 [0.38;1.40] 
History of Hepatitis C 
   
 
 
  No 
   
1 
   Yes 
   
1.54 [1.00;2.37] 
Health-Related Quality of Life (HRQL) 
   
 
 
  Normal 
   
1 
 
  Impaired mental  HRQL 
   
1.15 [0.77;1.72] 
  Impaired physical HRQL 
   
0.74 [0.50;1.08] 
  Impaired physical and mental HRQL 
 
  
1.07 [0.76;1.52] 
  Missing     0.86 [0.61;1.22] 
aPRR: adjusted prevalence rate ratio CI: confidence interval   *p<0.05   
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Figure 1. Labor market transitions following HIV diagnosis among participants of the VESPA-2003 and 
VESPA-2011 surveys diagnosed HIV-infected within the 36 months preceding interview 
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Supplementary material 
Table S1. Socio-demographic determinants of position on the labor market and health status 
characteristics of participants of the VESPA-2003 and VESPA-2011 surveys diagnosed HIV-infected within 
the 36 months preceding interview 
 
VESPA-2003 
a
 
(N=427) 
 
VESPA-2011 
a
 
(N=366) 
 P-value 
b 
Socio-demographic determinants of position on the labor market    
Sex 
 
 
 
  
Men 62.8  63.9  0.79 
Women 37.2  36.1  
 
Age (years) 
 
 
 
 
 25-39 56.8  54.6  0.84 
40-49 26.2  28.0  
 50-64 17.0  17.4   
Country of citizenship     
 France 56.6  58.0  0.14 
Sub-Saharan Africa 34.1  37.2  
 
Other 9.3  4.8  
 Educational level 
 
 
 
 
 High  29.0  33.5  0.31 
Low 71.0  66.5  
 
Household composition 
 
 
 
 
 Single, no children 37.5  35.4  0.61 
Single with children 10.2  14.6  
 Cohabiting partner, no children 22.5  21.8  
 Cohabiting partner and children 14.3  12.3  
 Other cohabiting adults 15.5  15.9  
 History of intravenous drug use      
No 97.7  98.2  0.66 
Yes 2.3  1.8  
 Health status 
 
 
 
 
 Immune status at HIV diagnosis 
 
 
 
 
 <200 CD4/mm
3
 or AIDS 37.6  29.1  0.03 
200-349 CD4/mm
3
 20.7  19.2  
 350-499 CD4/mm
3
 13.7  24.6  
 ≥500 CD4/mm
3
 24.1  23.6  
 Missing 3.9  3.5  
 ART status and HIV viral load (VL) 
 
 
 
 
 On ART, VL <400 copies/ml 57.1  69.7  0.01 
On ART, VL ≥400 copies/ml 10.2  4.4  
 Not on ART 31.1  23.0  
 Missing 1.6  2.9  
 History of Hepatitis C 
 
 
 
 
 No 94.0  97.0  0.05 
Yes 6.0  3.0  
 Health-Related Quality of Life (HRQL) 
 
 
 
 
 Normal 21.4  19.5  0.001 
Impaired mental HRQL 12.6  8.0  
 Impaired physical HRQL 13.3  20.9  
 Impaired physical and mental HRQL 14.5  24.6  
 Missing 38.2  27.0  
 a Weighted percentages 
b
 Chi-square test 
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